Cardiol Therapeutics (CRDL)
1.3600 -0.0700 (-4.90%)
Cardiol Therapeutics is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. The company is dedicated to advancing the treatment of heart conditions by leveraging its proprietary formulations and research into the therapeutic potential of cannabidiol, a compound derived from cannabis. Through rigorous scientific investigation and clinical trials, Cardiol aims to produce effective solutions that can improve quality of life for patients suffering from various heart-related ailments, with a vision of making significant contributions to the field of cardiology.
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.
Via MarketBeat · November 29, 2024
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Studybenzinga.com
Via Benzinga · November 19, 2024
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Todaybenzinga.com
Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering.
Via Benzinga · October 9, 2024
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesdaybenzinga.com
Via Benzinga · October 9, 2024
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024investorplace.com
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024
Stocks That Hit 52-Week Lows On Wednesdaybenzinga.com
On Wednesday, 200 companies hit new 52-week lows.
Via Benzinga · October 19, 2022
Stocks That Hit 52-Week Lows On Fridaybenzinga.com
During Friday's session, 198 companies made new 52-week lows.
Key Facts About Today's 52-Week Highs And Lows:
Alibaba Group Holding (NYSE:BABA) is the largest...
Via Benzinga · March 11, 2022
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via News Direct · June 17, 2024
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct · May 28, 2024
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024investorplace.com
CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs Inbenzinga.com
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via Benzinga · May 14, 2024
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023investorplace.com
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 2, 2024
Cardiol Therapeutics - This Penny Stock Is An Analysts Favoritetalkmarkets.com
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies.
Via Talk Markets · January 31, 2024
Cardiol Therapeutics (NASDAQ: CRDL)
Advancements in Therapies for Inflammatory Heart Diseases
--News Direct--
Via News Direct · October 13, 2023
Cardiol Therapeutics Fights Heart Inflammation With Novel Formulationsbenzinga.com
697,000 people die from heart disease every year in the United States – that is one in every five deaths.
Via Benzinga · October 12, 2023
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effectsbenzinga.com
On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous (SUBQ) formulati
Via Benzinga · October 10, 2023
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarketbenzinga.com
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.
Via Benzinga · September 21, 2023
Stocks That Hit 52-Week Lows On Tuesdaybenzinga.com
During Tuesday's session, 78 companies made new 52-week lows.
Via Benzinga · October 18, 2022
Stocks That Hit 52-Week Lows On Tuesdaybenzinga.com
On Tuesday, 44 companies hit new 52-week lows.
Via Benzinga · October 4, 2022
76 Biggest Movers From Yesterdaybenzinga.com
Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.
Via Benzinga · May 19, 2022
FDA Clears Cardiol Therapeutics' IND for CardiolRx in Recurrent Pericarditisbenzinga.com
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) from Cardiol Therapeutics Inc. (NASDAQ: CRDL) to start a Phase 2 open-label pilot study designed to evaluate the tolerance and safety of CardiolRx, in patients with recurrent pericarditis.
Via Benzinga · May 17, 2022
68 Biggest Movers From Yesterdaybenzinga.com
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Via Benzinga · April 19, 2022
34 Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....
Via Benzinga · April 18, 2022
51 Biggest Movers From Thursdaybenzinga.com
Gainers
MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...
Via Benzinga · April 18, 2022
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022benzinga.com
Upgrades
Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,...
Via Benzinga · March 17, 2022